In the 1, 040-patient study, patients with milder disease had a 42% lower reduction in how fast they declined on one version of the ADAS-cog test.

FORBES: An Alzheimer's Hope, Still Hanging On

But there were hints of efficacy: a 20% reduction in how fast patients declined on a different version of the ADAS-cog, and a 19% reduction on the Activities of Daily Living Inventory.

FORBES: An Alzheimer's Hope, Still Hanging On

When the mild patients from both studies are pooled together, the benefit of ADAS-cog is still significant, at a 34% reduction, and the benefit on the daily living inventory comes close to being statistically significant, a 17% decrease in how much worse patients got.

FORBES: An Alzheimer's Hope, Still Hanging On